Mirati Therapeutics traded at $71.18 this Friday July 1st, increasing $4.05 or 6.03 percent since the previous trading session. Looking back, over the last four weeks, Mirati Therapeutics gained 76.80 percent. Over the last 12 months, its price fell by 57.53 percent. Looking ahead, we forecast Mirati Therapeutics to be priced at 69.25 by the end of this quarter and at 63.77 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,838.00 26.00 0.68% 3.79%
Astellas Pharma 2,125.00 29.50 1.41% 11.58%
Eisai 5,825.00 0 0% -44.52%
Agios Pharmaceuticals 23.36 1.19 5.37% -58.08%
Alnylam Pharmaceuticals 148.25 2.40 1.65% -13.52%
Amgen 245.55 2.25 0.92% -1.27%
AstraZeneca 10,757.80 -50.20 -0.46% 23.36%
Bayer 55.34 -1.90 -3.32% 9.19%
BioCryst Pharmaceuticals 10.84 0.26 2.46% -34.22%
Bluebird Bio 4.28 0.14 3.38% -86.36%
Bristol-Myers Squibb 76.84 -0.16 -0.21% 14.77%
Exelixis 21.57 0.75 3.60% 18.13%
Gilead Sciences 62.36 0.55 0.89% -10.01%
GlaxoSmithKline 1,788.20 -14.40 -0.80% 24.68%
Incyte Corp 77.67 1.70 2.24% -7.07%
Ionis Pharmaceuticals 38.06 1.04 2.81% -4.66%
J&J 179.52 2.01 1.13% 6.24%
Eli Lilly 324.71 0.48 0.15% 38.79%
Merck & Co 92.42 1.25 1.37% 17.58%
Moderna Inc 149.95 7.10 4.97% -36.00%
Nektar Therapeutics 3.75 -0.05 -1.32% -78.08%
Novartis 80.69 -0.96 -1.18% -4.57%
Puma Biotechnology 2.78 -0.07 -2.46% -68.48%
Pfizer 52.31 -0.12 -0.23% 31.66%
Ultragenyx Pharmaceutical 62.65 2.99 5.01% -33.50%
Roche Holding 319.35 -3.25 -1.01% -9.66%
Seattle Genetics 180.11 3.17 1.79% 14.52%
Spectrum Pharmaceuticals 0.77 -0.01 -1.33% -78.86%
Sarepta Therapeutics 75.71 0.75 1.00% 0.62%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

Mirati Therapeutics
Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.